{"analyses":[{"ciLowerLimit":"1.91","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"24.82","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0237","pValueComment":"Not type I error controlled.","paramType":"Adjusted Difference","paramValue":"13.37","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37.90","upperLimit":"54.85","value":"46.4"},{"groupId":"OG001","lowerLimit":"25.18","upperLimit":"41.00","value":"33.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"136"}],"units":"Participants"}],"description":"CRR with serum creatinine criteria was defined as achievement of all the following criteria: UPCR \\<0.5 g/g; Serum creatinine ≤ ULN, as determined by the central laboratory; serum creatinine not increased from baseline by \\> 25% and no occurrence of intercurrent events of rescue therapy, treatment failure, death or early study withdrawal. Analysis was performed using CMH test adjusting for the stratification factors region and race. Percentage have been rounded off.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received obinutuzumab, 1000 mg as an IV infusion on Day 1 and Weeks 2, 24, 26, and either Weeks 50 and 52 or Week 52 only, along with MMF and SOC therapy. Placebo was administered at Week 50 for participants not treated with obinutuzumab. Participants with adequate response at Week 76 continued to receive obinutuzumab at Week 80 and Q6M thereafter. The dose of MMF can be adjusted at the investigator's discretion beginning at Week 80.","id":"OG000","title":"Obinutuzumab"},{"description":"Participants received Obinutuzumab matching placebo as an IV infusion on Day 1 and Weeks 2, 24, 26, 50, and 52. Participants also received SOC therapy and MMF. Participants with adequate response at Week 76 continued to receive placebo at Week 80 and Q6M thereafter.","id":"OG001","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"Efficacy population included all randomized participants regardless of whether they received study drug. As pre-specified in the SAP, all the endpoints were to be compared between the obinutuzumab (combined treatment groups) and placebo groups.","reportingStatus":"POSTED","timeFrame":"At Week 76","title":"Percentage of Participants Who Achieve CRR With Serum Creatinine Criteria","type":"SECONDARY","unitOfMeasure":"percentage of participants"}